Sorry, you need to enable JavaScript to visit this website.

GREENSTONE LLC INTRODUCES
LINEZOLID FOR ORAL SUSPENSION
Authorized Generic of ZYVOX (linezolid for oral suspension)

PEAPACK, NJ, November 2015 — Greenstone LLC, a U.S.-based subsidiary of Pfizer Inc (NYSE: PFE), is pleased to announce the introduction of linezolid for oral suspension to its ever-expanding generic pharmaceutical product line. The product is offered in powder form in dosage strengths of 100 mg / 5 mL x 150 mL as reconstituted suspension.

Greenstone’s linezolid for oral suspension product is the authorized generic of, and equivalent to the innovator’s product, ZYVOX (linezolid for oral suspension). This new authorized generic adds to Greenstone’s consistently growing line of products, and is backed by the distribution and customer service support of Pfizer Inc., one of the world’s premiere biopharmaceutical companies. As a subsidiary of Pfizer, Greenstone operates under the same values and commitment to bring quality authorized generics to customers, payers, and the patients it serves.

See the Full Prescribing Information for Greenstone’s linezolid for oral suspension at http://www.greenstonellc.com/product-list.aspx.

For more information about Greenstone LLC and its products, visit http://greenstonellc.com.

Zyvox is a registered trademark of C.P. Pharmaceuticals International C.V.